ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036C

Also written as “MHB036C” and “MHB036C for Injection”.

Its studies are mostly in Breast Neoplasms, led by Minghui Pharmaceutical.

Drug pageAnti-TROP-2/Topoisomerase Inhibitor ADC MHB036C: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Nov 30, 20223 company-led studies, 3 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Minghui Pharmaceutical33 open or runningphase 2since Nov 30, 2022Nov 30, 2022Apr 2027phase 2 · NCT06373406

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05642949 · 400 planned · Australia
  2. Apr 15, 2024Phase 2 study in Advanced Solid TumorNCT06373406 · 200 enrolled · China
  3. Aug 12, 2025Phase 2 study in Advanced Breast CancerNCT07130383 · 210 planned · China
  4. Oct 16, 2026Primary completion moved from 2025-12 to 2027-04Date moved laterphase 2 · +16 months · NCT06373406

Ahead

  1. Apr 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06373406
  2. Aug 2029Primary completion: phase 2 study in Advanced Breast CancerNCT07130383

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07130383Advanced Breast Cancer · China2RecruitingAug 2029210
NCT06373406Advanced Solid Tumor · China2Active, not recruitingApr 2027200
NCT05642949Advanced Solid Tumor · Australia2Not yet recruitingDec 31, 2025400

How it is read

Names in the registry

  • “MHB036C”, 2 entries
  • “MHB036C for Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.